Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Johnson & Johnson/Gilead Deal Could Yield More Combinations in HIV

Johnson & Johnson/Gilead Deal Could Yield More Combinations in HIV

Healthcare Sector and Stocks Analysis from Seeking Alpha

Thu, 30 Jun 2011

EP Vantage submits: Johnson and Johnson 's ( JNJ ) new licensing agreement with Gilead Sciences ( GILD ) for its protease inhibitor Prezista to develop a new combination drug using booster drug cobicistat says a lot about the clever life-cycle management strategy J&J has come up with for the drug. ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Related Videos

  1. Why J&J Bought a Big Piece of Elan

    Fri, 4 Dec 2009

    Morningstar's Damien Conover and Alex Morozov discuss what J&J's stake in biotech Elan means for both companies.

  2. Upside Attraction to J&J

    Fri, 4 Dec 2009

    Morningstar's Damien Conover discusses the prospects for J&J's stent and drug pipelines.

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.